| Dr Lakpa Diku Sherpa, MD | |
|
900 Caton Ave, Baltimore, MD 21229-5201 | |
| (667) 234-3120 | |
| Not Available |
| Full Name | Dr Lakpa Diku Sherpa |
|---|---|
| Gender | Female |
| Speciality | Hospitalist |
| Experience | 22 Years |
| Location | 900 Caton Ave, Baltimore, Maryland |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1396094983 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | MD20584 (Maine) | Secondary |
| 208M00000X | Hospitalist | D88098 (Maryland) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Saint Agnes Hospital | Baltimore, MD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| St. Agnes Healthcare, Inc. | 9830092733 | 237 |
News Archive
A new type of anti-epilepsy medication that selectively targets proteins in the brain that control excitability may significantly reduce seizure frequency in people whose recurrent seizures have been resistant to even the latest medications, new Johns Hopkins-led research suggests.
In 1998, a study linking the measles, mumps and rubella vaccine to autism in children appeared in a respected medical journal. For a decade, the study grabbed headlines worldwide.
The U.S. Food and Drug Administration today approved Dovato (dolutegravir and lamivudine), as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults with no antiretroviral treatment history and with no known or suspected substitutions associated with resistance to the individual components of Dovato.
Feeding tubes are not as harmless as they seem. Every year in the U.S. over 40,000 feeding tubes are mistakenly placed into a patient's lungs, which results in an estimated 6,000 deaths. But a University of Utah startup company, Veritract Inc., hopes to end these risks by making the placement of feeding tubes much safer and faster.
Seaside Therapeutics, Inc. announced today data from the largest randomized, placebo-controlled study conducted to date in individuals with fragile X syndrome. In a Phase 2 study of STX209, clinically meaningful improvements on global and specific neurobehavioral outcomes were observed in the general study population. The improvements were statistically significant in pediatric patients with more severe impairments in sociability - a core symptom of fragile X syndrome.
› Verified 9 days ago
| Entity Name | St. Agnes Healthcare, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144250176 PECOS PAC ID: 9830092733 Enrollment ID: O20040128001146 |
News Archive
A new type of anti-epilepsy medication that selectively targets proteins in the brain that control excitability may significantly reduce seizure frequency in people whose recurrent seizures have been resistant to even the latest medications, new Johns Hopkins-led research suggests.
In 1998, a study linking the measles, mumps and rubella vaccine to autism in children appeared in a respected medical journal. For a decade, the study grabbed headlines worldwide.
The U.S. Food and Drug Administration today approved Dovato (dolutegravir and lamivudine), as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults with no antiretroviral treatment history and with no known or suspected substitutions associated with resistance to the individual components of Dovato.
Feeding tubes are not as harmless as they seem. Every year in the U.S. over 40,000 feeding tubes are mistakenly placed into a patient's lungs, which results in an estimated 6,000 deaths. But a University of Utah startup company, Veritract Inc., hopes to end these risks by making the placement of feeding tubes much safer and faster.
Seaside Therapeutics, Inc. announced today data from the largest randomized, placebo-controlled study conducted to date in individuals with fragile X syndrome. In a Phase 2 study of STX209, clinically meaningful improvements on global and specific neurobehavioral outcomes were observed in the general study population. The improvements were statistically significant in pediatric patients with more severe impairments in sociability - a core symptom of fragile X syndrome.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Lakpa Diku Sherpa, MD 900 Caton Ave, Baltimore, MD 21229-5201 Ph: (667) 234-3120 | Dr Lakpa Diku Sherpa, MD 900 Caton Ave, Baltimore, MD 21229-5201 Ph: (667) 234-3120 |
News Archive
A new type of anti-epilepsy medication that selectively targets proteins in the brain that control excitability may significantly reduce seizure frequency in people whose recurrent seizures have been resistant to even the latest medications, new Johns Hopkins-led research suggests.
In 1998, a study linking the measles, mumps and rubella vaccine to autism in children appeared in a respected medical journal. For a decade, the study grabbed headlines worldwide.
The U.S. Food and Drug Administration today approved Dovato (dolutegravir and lamivudine), as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults with no antiretroviral treatment history and with no known or suspected substitutions associated with resistance to the individual components of Dovato.
Feeding tubes are not as harmless as they seem. Every year in the U.S. over 40,000 feeding tubes are mistakenly placed into a patient's lungs, which results in an estimated 6,000 deaths. But a University of Utah startup company, Veritract Inc., hopes to end these risks by making the placement of feeding tubes much safer and faster.
Seaside Therapeutics, Inc. announced today data from the largest randomized, placebo-controlled study conducted to date in individuals with fragile X syndrome. In a Phase 2 study of STX209, clinically meaningful improvements on global and specific neurobehavioral outcomes were observed in the general study population. The improvements were statistically significant in pediatric patients with more severe impairments in sociability - a core symptom of fragile X syndrome.
› Verified 9 days ago
Allison Weaver, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 600 N Wolfe Street, Meyer 8-134, Baltimore, MD 21287 Phone: 410-614-4474 Fax: 410-367-2770 | |
Cheryl Myers Hepp, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 22 S Greene St, Baltimore, MD 21201 Phone: 410-328-2882 Fax: 410-328-7607 | |
Omid Sanaei, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 201 E University Pkwy, Baltimore, MD 21218 Phone: 410-554-2284 Fax: 410-554-2184 | |
Sumedha Nallamothu, M.B.B.S Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 600 N Wolfe Street, Meyer 8-134, Baltimore, MD 21287 Phone: 410-614-4474 Fax: 410-367-2770 | |
Dr. Nejat Ahmed Mohammed, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 3001 S Hanover St, Baltimore, MD 21225 Phone: 410-350-3200 | |
Mahyar Toofantabrizi, Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 9000 Franklin Square Dr, Baltimore, MD 21237 Phone: 443-777-7000 | |
Lee-ann Marie Wagner, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 22 S Greene St, Baltimore, MD 21201 Phone: 410-328-2882 Fax: 410-328-7607 |